抗NMDA受体脑炎和精神分裂症相关性研究进展(4)
[15] Titulaer MJ，Dalmau J.Antibodies to NMDA receptor，blood-brain barrier disruption and schizophrenia：A theory with unproven links[J]. Molecular Psychiatry，2014， 19(10)：1054.
[16] Mohagheghi M，Eftekharian MM，Taheri M，et al. Determining the IgM and IgG antibodies titer against HSV1，HSV2 and CMV in the serum of schizophrenia patients[J].Hum Antibodies，2018，26(2)：87-93.
[17] Kannan G，Crawford JA，Yang C，et al. Anti-NMDA receptor autoantibodies and associated neurobehavioral pathology in mice are dependent on age of first exposure to Toxoplasma gondii[J]. Neurobiol Dis，2016，91：307-314.
[18] Miyamoto S，Miyake N，Jarskog LF，et al. Pharmacological treatment of schizophrenia： A critical review of the pharmacology and clinical effects of current and future therapeutic agents[J]. Molecular Psychiatry，2012，17(12)：1206-1227.
[19] Kantrowitz JT，Woods SW，Petkova EC，et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia：a pilot，double-blind， placebo-controlled，randomised parallel group mechanistic proof-of-concept trial[J]. Lancet Psychiatry，2015，2(5)：403-412.
[20] Lennox BR，Deakin J，Zandi M，et al. Anti neuronal cell surface antibodies as a cause of schizophrenia[J]. Schi-zophrenia Bulletin，2015，39(Suppl 1)：S1-S358.
(收稿日期：2019-01-24), 百拇医药(许委娟 许毅)
[16] Mohagheghi M，Eftekharian MM，Taheri M，et al. Determining the IgM and IgG antibodies titer against HSV1，HSV2 and CMV in the serum of schizophrenia patients[J].Hum Antibodies，2018，26(2)：87-93.
[17] Kannan G，Crawford JA，Yang C，et al. Anti-NMDA receptor autoantibodies and associated neurobehavioral pathology in mice are dependent on age of first exposure to Toxoplasma gondii[J]. Neurobiol Dis，2016，91：307-314.
[18] Miyamoto S，Miyake N，Jarskog LF，et al. Pharmacological treatment of schizophrenia： A critical review of the pharmacology and clinical effects of current and future therapeutic agents[J]. Molecular Psychiatry，2012，17(12)：1206-1227.
[19] Kantrowitz JT，Woods SW，Petkova EC，et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia：a pilot，double-blind， placebo-controlled，randomised parallel group mechanistic proof-of-concept trial[J]. Lancet Psychiatry，2015，2(5)：403-412.
[20] Lennox BR，Deakin J，Zandi M，et al. Anti neuronal cell surface antibodies as a cause of schizophrenia[J]. Schi-zophrenia Bulletin，2015，39(Suppl 1)：S1-S358.
(收稿日期：2019-01-24), 百拇医药(许委娟 许毅)